We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+56.58%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$541M
AUM Growth
+$64M
Cap. Flow
-$9.38M
Cap. Flow %
-1.73%
Top 10 Hldgs %
55.94%
Holding
50
New
10
Increased
10
Reduced
13
Closed
12

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$31.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$20M
3
EXAS
Exact Sciences
EXAS
+$12.4M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$11.6M
5
IRON icon
Disc Medicine
IRON
+$11.1M

Top Sells

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$30.6M
2
GILD icon
Gilead Sciences
GILD
+$25.2M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.6M
4
CORT icon
Corcept Therapeutics
CORT
+$17.6M
5
BBIO icon
BridgeBio Pharma
BBIO
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
26
Protara Therapeutics
TARA
$232M
$6.53M 1.21%
1,500,793
-125,577
-8% -$407K
SEPN
27
Septerna Inc
SEPN
$1.75B
$5.54M 1.02%
294,360
– –
CDTX
28
DELISTED
Cidara Therapeutics
CDTX
$5.11M 0.94%
+53,333
New +$3.4M
KYTX icon
29
Kyverna Therapeutics
KYTX
$484M
$3.52M 0.65%
586,909
– –
ELDN icon
30
Eledon Pharmaceuticals
ELDN
$285M
$2.75M 0.51%
+1,061,132
New +$3.1M
OM icon
31
Outset Medical
OM
$90.8M
$1.67M 0.31%
118,279
-48,387
-29% -$754K
MGX icon
32
Metagenomi Therapeutics
MGX
$46.3M
$1.25M 0.23%
528,993
– –
ATAI icon
33
AtaiBeckley Inc
ATAI
$2.68B
$1.04M 0.19%
196,858
– –
HYPR icon
34
Hyperfine
HYPR
$101M
$993K 0.18%
684,541
-75,494
-10% -$88.1K
MLTX icon
35
MoonLake Immunotherapeutics
MLTX
$1.55B
$955K 0.18%
133,131
-29,465
-18% -$1.54M
KPTI icon
36
Karyopharm Therapeutics
KPTI
$48M
$935K 0.17%
142,984
-3,029
-2% -$16.3K
PVLA
37
Palvella Therapeutics
PVLA
$2.27B
$753K 0.14%
+12,010
New +$536K
FTH
38
Faeth Therapeutics
FTH
$629M
$139K 0.03%
14,718
– –
CORT icon
39
Corcept Therapeutics
CORT
$12B
– –
-239,125
Closed -$17.6M
EW icon
40
Edwards Lifesciences
EW
$51.7B
– –
-390,932
Closed -$30.6M
FULC icon
41
Fulcrum Therapeutics
FULC
$297M
– –
-188,304
Closed -$1.3M
GILD icon
42
Gilead Sciences
GILD
$165B
– –
-226,875
Closed -$25.2M
HALO icon
43
Halozyme
HALO
$12.2B
– –
-191,529
Closed -$9.96M
MRSN
44
DELISTED
Mersana Therapeutics
MRSN
– –
-62,697
Closed -$464K
REPL icon
45
Replimune Group
REPL
$1.01B
– –
-330,337
Closed -$3.07M
TEVA icon
46
Teva Pharmaceuticals
TEVA
$41.2B
– –
-1,170,372
Closed -$19.6M
VIR icon
47
Vir Biotechnology
VIR
$1.49B
– –
-388,303
Closed -$1.96M
WGS icon
48
GeneDx Holdings
WGS
$2.3B
– –
-61,507
Closed -$5.68M
BCAX
49
Bicara Therapeutics
BCAX
$1.84B
– –
-97,800
Closed -$909K
ZBIO
50
Zenas BioPharma
ZBIO
$2.05B
– –
-215,314
Closed -$2.09M
1
2

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
DA
Dash Acquisitions Woodland Hills, California $480M AUM 4.07% 1-Year Est. Return
NQWM
Northwest Quadrant Wealth Management Bend, Oregon $481M AUM 13.55% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $481M AUM 46% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM

Catalio Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Catalio Capital Management held 50 positions worth $541M, up 13% from $477M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Catalio Capital Management's Q3 2025 filing shows 10 new, 10 increased, 13 reduced and 12 closed positions. Its largest new stake was AbbVie: 154,834 shares worth $35.9M. The largest sale was Edwards Lifesciences, an estimated $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Catalio Capital Management's largest Q3 2025 buy was AbbVie: 154,834 shares worth $35.9M.
  • Catalio Capital Management added most to Disc Medicine in Q3 2025, an estimated $11.1M increase.
  • Catalio Capital Management's biggest Q3 2025 reduction was BridgeBio Pharma, cutting an estimated $14.9M.
  • Catalio Capital Management fully exited Edwards Lifesciences in Q3 2025, selling an estimated $30.6M.
  • Catalio Capital Management's ten largest holdings make up 56% of its $541M portfolio in Q3 2025.
  • Catalio Capital Management opened 10 new positions and closed 12 in Q3 2025.
  • Catalio Capital Management's portfolio value rose 13% quarter-over-quarter to $541M.

Based on Catalio Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.